Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has shared an announcement.
Telix Pharmaceuticals Limited has completed the acquisition of FAP-targeting theranostic candidates, expanding its pipeline with new compounds aimed at Fibroblast Activation Protein, a promising target in nuclear medicine for cancer treatment. This strategic acquisition enhances Telix’s urology focus and pan-cancer therapeutic potential, positioning the company to deliver innovative theranostic solutions and strengthen its market presence in oncology.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Canada, Europe, and Japan, and is listed on the Australian Securities Exchange and Nasdaq. The company aims to address significant unmet medical needs in oncology and rare diseases through its portfolio of clinical and commercial stage products.
YTD Price Performance: 14.50%
Average Trading Volume: 4,747
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.85B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.